Drug Profile

SZ 005

Alternative Names: SZ-005

Latest Information Update: 28 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sarfez Pharmaceuticals
Class Antihyperglycaemics; Antihypertensives; Heart failure therapies; Urologics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

No development reported Diabetes mellitus; Heart failure; Hypertension; Kidney disorders

28 Aug 2024 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
28 Aug 2024 No recent reports of development identified for preclinical development in Heart-failure in USA
28 Aug 2024 No recent reports of development identified for research development in Hypertension in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com